Peptide deformylase (PDF), a clinically unexploited antibacterial target, plays an essential role in protein maturation. PDF inhibitors, therefore, represent a new antibiotic class with a unique mode of action that provides an alternative therapy for the treatment of infections caused by drug-resistant pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). GSK1322322 is a novel PDF inhibitor that is in phase II clinical development for the treatment of lower respiratory tract and skin infections. We have discovered that PDF inhibitors can prevent S. aureus in vitro growth for up to 6 h at concentrations 8-to 32-fold below their MICs. This phenomenon seems specific to PDF inhibitors, as none of the antimicrobial agents with alternative mechanisms of action tested show such a potent and widespread effect. It also appears limited to S. aureus, as PDF inhibitors do not show such an inhibition of growth at sub-MIC levels in Streptococcus pneumoniae or Haemophilus influenzae. Analysis of the effect of GSK1322322 on the early growth of 100 randomly selected S. aureus strains showed that concentrations equal to or below 1/8؋ MIC inhibited growth of 91% of the strains tested for 6 h, while the corresponding amount of moxifloxacin or linezolid only affected the growth of 1% and 6% of strains, respectively. Furthermore, the sub-MIC effect demonstrated by GSK1322322 appears more substantial on those strains at the higher end of the MIC spectrum. These effects may impact the clinical efficacy of GSK1322322 in serious infections caused by multidrug-resistant S. aureus.
R
esistance to marketed antibiotics has been a global health concern for a number of years, particularly with the appearance of strains resistant to multiple antimicrobial agents. Staphylococcus aureus accounts for 16% of the most common hospital-acquired infections (HAIs), the highest number associated with a single pathogen (1) , with methicillin-resistant S. aureus (MRSA) being responsible for more than 50% of them (1) . Although there have been encouraging reports that show a decrease in the number of invasive health care-associated MRSA infections (HA-MRSA) (1, 2), a continuous increase in the number of invasive communityassociated MRSA (CA-MRSA) infections has been observed in the last decade (3) .
PDF is a highly conserved metalloprotease that catalyzes the removal of the N-terminal formyl group from all nascent polypeptides (4-6), a function essential for bacterial growth (7) (8) (9) (10) and, therefore, an attractive target for the development of new broad-spectrum antibacterial agents. The considerable effort invested over the past decade into the discovery of PDF inhibitors for clinical use has yielded a significant number of chemically diverse molecules with antibacterial activity and efficacy in animal models of infection (11) (12) (13) . One compound, GSK1322322 (14) , has shown good safety and pharmacokinetic properties (15) (16) (17) (18) and is currently in phase II development.
In this study, we report that GSK1322322 and other PDF inhibitors can prevent S. aureus in vitro growth for 6 h at concentrations 8-to 32-fold below their MICs. This effect seems specific to S. aureus and PDF inhibitors and is not consistently observed with other antibiotics with alternative bacterial targets, or with PDF inhibitors against other organisms.
MATERIALS AND METHODS
Bacterial strains and growth conditions. One hundred S. aureus clinical isolates (75 MRSA and 25 methicillin-sensitive S. aureus [MSSA] ; International Health Management Associates, Schaumburg, IL), randomly selected from a larger GSK1322322 in vitro surveillance study (14) , were used in this analysis. Additional S. aureus (124429, PK2, Newman, and X32601), Streptococcus pneumoniae (1629, Ery-2, 1302005S, and ATCC 6303), and Haemophilus influenzae (511343, 503-008H, L317/3, and H128) strains used were obtained from the GlaxoSmithKline Anti-Infectives Culture Collection. S. pneumoniae and S. aureus strains were cultured at 35°C on Trypticase soy agar (TSA) with 5% sheep blood or in cation-adjusted Mueller-Hinton broth. H. influenzae strains were cultured at 35°C on chocolate agar II plates or in haemophilus test medium broth.
Antimicrobial agents and susceptibility testing. PDF inhibitors GSK1322322 and GSK466222 (19) were obtained from GlaxoSmithKline Pharmaceuticals (Collegeville, PA). Other antibacterial agents used in this analysis were provided by their manufacturers in the United States or by Sigma Pharmaceuticals (Monticello, IA). MICs were determined by broth microdilution according to Clinical and Laboratory Standards Institute guidelines (20) .
Bacterial count viability assay. In order to determine the number of viable bacterial cells, samples were removed at regular time intervals from the different wells of standard MIC plate assays, in which every time point was an independent MIC study. Viable bacterial counts were performed at assay setup (time zero) and every 2 h up to 20 h of incubation, by plating three 20-l aliquots from each MIC assay well onto the appropriate agar plates. Plates were incubated overnight at 35°C, and colony counts were determined at the dilution that provided distinguishable colonies (10 to 50 colonies, depending on bacterial species). An average of the three counts was used to estimate the number of CFU per ml in the original sample.
BacTitre-Glo viability assay. The BacTitre-Glo microbial cell viability assay (Promega, Madison, WI) determines the number of viable bacterial cells in a liquid sample through quantification of ATP production by addition of a thermostable luciferase and measurement of the luminescent signal. This assay is amenable to high throughput and provides a more direct and immediate measurement of bacterial viability (21) . Samples (50 l) were taken from each compound concentration in a standard MIC plate after 6 h of incubation, and ATP production was measured as the relative light units (RLU) according to the manufacturer's recommendations, using an Infinite microplate reader (Tecan US, Morrisville, NC).
The percent inhibition of growth was calculated as follows: {1 Ϫ [(RLU of sample Ϫ background)/(RLU of control Ϫ background)]} ϫ 100, where the RLU of the sample was the RLU in each compound-containing well, RLU of the control was the RLU in the no-compound well, and the background was the RLU in the 4ϫ MIC well.
This assay was carried out in duplicate using two inoculum preparations in separate assay plates in order to assess reproducibility and to increase confidence in the data. Good reproducibility of ATP quantification between the duplicate trials was observed, with the concentration of compound that reduced growth by 95% being the same or within 2-fold in most cases. When the results varied Ͼ2-fold, the percent inhibition was calculated from the average of both ATP quantifications. In those cases where the results differed by Ն4-fold, the assay was repeated in duplicate.
A linear correlation was observed between luminescent signal and the number of cells present in cultures of S. aureus strains PK2, 124429, Newman, and X32601, with coefficients of determination (R 2 values) for the two sets of data of 0.89, 0.93, 0.99, and 0.99, respectively.
Mice. Male CD-1 mice (body weights of 20 to 25 g; Charles River Laboratories, Wilmington, MA) used in the experimental models were allowed food and water ad libitum. All procedures were performed in accordance with protocols approved by the GlaxoSmithKline Institutional Animal Care and Use Committee and met or exceeded the standards of the American Association for the Accreditation of Laboratory Animal Care, the U.S. Department of Health and Human Services, and all local and federal animal welfare laws.
Murine groin infection model. S. aureus cultures, grown overnight in brain heart infusion broth, were diluted 1:20 into phosphate-buffered saline (PBS). Bacterial suspensions were further diluted 1:10 into 0.6% (wt/vol) semisolid nutrient agar. Six mice/group were inoculated with 0.5 ml of this suspension (containing approximately 2 ϫ 10 6 CFU/mouse) by subcutaneous injection in the femoral region. Starting 1 h after infection, mice were dosed with GSK466222 twice daily for 4 days. The mice were euthanized 96 h after infection, and the abscess was removed, placed into a stomacher bag with 1 ml of PBS, and homogenized for 2 min in a Stomacher 80 Biomaster (Seward). Tenfold serial dilutions in sterile saline were plated on TSA supplemented with 5% sheep blood for enumeration of viable bacteria.
Quantification of GSK466222 in blood samples. Approximately 30 ml of whole blood was serially collected from the lateral tail vein of mice at 0.083, 0.25, 0.5, 1, 2, 4, 8, 10, and 24 h postdosing into heparin-coated capillary tubes (Drummond Scientific, Broomall, PA). Blood (10 ml) was transferred into a microcentrifuge tube and mixed with 10 ml cold highperformance liquid chromatography-grade water. All samples were frozen immediately on dry ice and maintained at Ϫ80°C until analyzed via liquid chromatography-tandem mass spectrometry with the appropriate concentration curve.
RESULTS
Efficacy of GSK466222 against S. aureus strains in a murine groin abscess infection model was, in some cases, better than expected. A substantial number of PDF inhibitors demonstrated good in vivo activity in murine S. aureus groin abscess infection models, despite having free-fraction blood levels that did not always reach their MICs. Therefore, a study was designed to evaluate the oral efficacy of GSK466222 against three S. aureus strains with MICs of 0.5, 2, and 8 g/ml. As depicted in Fig. 1A and B, the efficacy of GSK466222 administered orally at 150 mg/kg of body weight was similar among all strains, despite the fact that free blood drug levels peaked at 1.05 g/ml and never achieved the MIC of the compound against two of the three strains.
PDF inhibitors prevent initial S. aureus growth at concentrations as low as 16-fold below their MIC. In order to improve our understanding of the inhibitory effect of PDF inhibitors on S. aureus growth, a study was carried out to determine the number of viable bacterial cells in the wells of a standard MIC plate with GSK466222 and S. aureus 124429 (MIC of 4 g/ml). The study was completed as two separate experiments with samples taken at time points between 0 and 10 h on day 1 and at time points between 12 and 20 h on day 2 ( Fig. 2A) . Concentrations of GSK466222 as low as 0.25 g/ml (1/16ϫ MIC) prevented growth of this S. aureus strain during the first 6 h, and 0.5 g/ml (1/8ϫ MIC) prevented growth for 8 h (Fig. 2A) . However, as expected, after the standard 16-to 20-h incubation, the GSK466222 MIC for this organism was 4 g/ml. An identical MIC pattern was observed when the bacterial inoculum was obtained from wells treated with sub-MIC levels of GSK466222, indicating that the growth observed at 20 h was not the consequence of resistance development.
Similar to the results obtained with S. aureus 124429, both GSK466222 and an additional PDF inhibitor, GSK1322322, demonstrated strong inhibition of S. aureus PK2 growth for 6 h at 1/16 MIC (Fig. 2B) . On the other hand, sub-MICs of moxifloxacin and linezolid did not significantly inhibit growth of S. aureus PK2 after the first 2 h. Rapid killing could be seen with moxifloxacin at MICs up to 8 h of incubation, but there was growth at 1/4ϫ MIC and 1/8ϫ MIC after 2 h of incubation (Fig. 2B) . Linezolid showed inhibition of growth at concentrations corresponding to 1/4ϫ MIC for the first 6 to 8 h of incubation, but at concentrations of 1/8ϫ and 1/16ϫ MIC there was significant growth after 2 h (Fig. 2B) .
In order to further investigate the extent of these findings and to determine if the phenomenon was limited to S. aureus, BacTitre-Glo was used to assess the effect of a larger number of compounds against a broader diversity of organisms after 6 h of incubation.
The second methodology confirmed a potent inhibitory effect of PDF inhibitors on initial S. aureus growth at sub-MIC levels. Cell growth was evaluated, via ATP production, in four S. aureus cultures (strains PK2, 124429, Newman, and X32601) in the presence of various multiples and fractions of the MICs of three PDF inhibitors and other standard antibacterial agents (Table 1). A potent growth-inhibitory effect was consistently observed in these four S. aureus strains at concentrations between 1/8ϫ and 1/32ϫ their respective MICs only with PDF inhibitors, although mupirocin and tetracycline prevented growth of S. aureus Newman at levels of 1/8ϫ and 1/32ϫ MIC, respectively.
To clarify whether this effect was unique to S. aureus, growth inhibition studies were performed with four strains each of S. pneumoniae and H. influenzae in the presence of variable amounts of GSK466222 or moxifloxacin (Table 1) . For both organisms, concentrations of GSK466222 near the MIC were necessary to inhibit 95% of bacterial growth (Table 1) .
Sub-MICs of GSK1322322 inhibited growth of 91% of S. aureus strains for 6 h. In order to ascertain the breadth of this finding with S. aureus, inhibition of growth of 100 randomly selected S. aureus strains was assessed after 6 h of incubation at various multiples and fractions of the MICs of GSK1322322, moxifloxacin, and linezolid. MICs for these strains ranged from 0.5 to 4 g/ml for GSK1322322, 1 to 4 g/ml for linezolid, and 0.03 to 16 g/ml for moxifloxacin. Only 99 strains were tested with moxifloxacin, as one was highly resistant to this antibiotic (MIC, Ͼ32 g/ml).
Moxifloxacin showed no significant growth inhibition at subMICs in 98 of the 99 strains tested after 6 h of incubation (Fig. 3) . Growth inhibition of Ն95% was achieved at moxifloxacin concentrations of 1/8ϫ MIC in only one case, whereas four strains needed 1/2ϫ MIC and the additional 94 strains required levels at the MICs or greater.
With linezolid, 90 of the 100 strains tested had Ն95% of growth inhibited at concentrations 4-fold below the MIC, and 4/100 strains required 1/2ϫ MICs. This compound had an initial potent sub-MIC effect in 6 of the 100 strains, with substantial growth inhibition at 1/8ϫ MIC (Fig. 3) .
In contrast, GSK1322322 demonstrated a strong sub-MIC in- hibitory effect, with Ն95% of growth of 91 of the 100 strains inhibited at concentrations of 1/8ϫ MIC or lower (Fig. 3) . In fact, concentrations of 1/16ϫ MIC or below inhibited growth of 62% of the strains after 6 h of incubation, and one isolate showed Ն95% growth inhibition at 1/128ϫ MIC. Of the remaining 9 isolates, 8 required concentrations of 1/4 MICϫ and 1 required 1/2ϫ MIC to prevent Ն95% of growth. Relationship between GSK1322322 MIC and the fraction of the MIC necessary to inhibit >95% of S. aureus growth. A detailed analysis of the data demonstrated that the initial growth of strains with the highest GSK1322322 MICs could be prevented with smaller MIC fractions (Fig. 4) . In fact, concentrations equal to or below 1/16ϫ MIC inhibited early growth of 41% (7/17), 69% (49/71), and 83% (5/6) of the strains at MICs of 1, 2, and 4 g/ml, respectively. Although few strains with MICs at both ends of the spectrum (0.5 and 4 g/ml) were included in this study, concentrations equal to or lower than 1/8ϫ GSK1322322 MIC did not show an inhibitory effect against most of the isolates with the lowest MIC, whereas they did against 97% (69/71) and 100% (6/6) of the strains with MICs of 2 and 4 g/ml, respectively (Fig. 4) .
DISCUSSION
S. aureus is a commensal organism with a versatile arsenal of virulence factors that enable it to invade and colonize all types of tissues and to evade host defenses (22) . This bacterium is the causative agent of a number of common infections in skin, soft tissue, respiratory system, joints, and bones and is responsible for lifethreatening clinical conditions, such as pneumonia, bacteremia, endocarditis, and toxic shock syndrome (22) .
PDF is one of only a few clinically unexploited targets with an antimicrobial candidate agent in development. This enzyme is ubiquitous in bacteria, where it plays an essential role in protein (2) 1ϫ (2) a Data in shaded cells indicate that the concentration of the antibiotic used inhibited growth of the strain at Յ1/8ϫ MIC. ND, not determined for that S. aureus strain. b Two strains were resistant to azithromycin.
maturation, and it is not necessary for eukaryotic cytoplasmic protein synthesis, which starts with unformylated methionine. Inhibitors of PDF have demonstrated activity against S. aureus in vitro (12, (23) (24) (25) (26) , in animal models of infection (27) , and in a phase IIa study (R. Corey, O. J. Naderer, W. O'Riordan, E. Dumont, L. S. Jones, submitted for publication). Unexpected results showing better-than-anticipated efficacy of PDF inhibitors in murine S. aureus groin abscess infection models prompted an investigation into the effect of these compounds on the in vitro growth of S. aureus. Initial experiments showed a pronounced inhibitory effect of PDF inhibitors GSK466222 and GSK1322322 on the first 6 to 8 h of S. aureus growth at concentrations 8-to 16-fold below the MIC, which was not observed with the bactericidal DNA gyrase inhibitor moxifloxacin or the bacteriostatic protein synthesis inhibitor linezolid. More-extensive studies investigating the effects of three PDF inhibitors and 10 comparator agents with different modes of antibacterial action on S. aureus growth corroborated these results. All the PDF inhibitors could prevent Ն95% of the growth of four S. aureus strains for 6 h at concentrations ranging between 1/8ϫ and 1/32ϫ their respective MICs. None of the other antimicrobial agents showed such a potent and widespread sub-MIC effect, although linezolid demonstrated consistent growth inhibition of all strains at 1/4ϫ the MICs. This property of PDF inhibitors may be limited primarily to S. aureus, as sub-MICs did not have such a profound effect on the growth of S. pneumoniae or H. influenzae strains.
A study comparing the effects of GSK1322322, linezolid, and moxifloxacin on the first 6 h of growth of 100 randomly selected S. aureus strains showed that concentrations 8-fold below the GSK1322322 MIC inhibited Ն95% of growth of 91% of the strains, while the corresponding amounts of moxifloxacin or linezolid could only prevent growth of 1% and 6% of the strains, respectively. Analysis of the relationship between the GSK1322322 MIC and the fraction of the MIC necessary to inhibit Ն95% of the early S. aureus growth revealed an interesting trend that, if confirmed, could have clinical implications for this compound. Concentrations of GSK1322322 equal to or below 1/8ϫ MIC had a potent inhibitory effect on the early growth of only 25% (1/4) of S. aureus strains with MICs of 0.5 g/ml, but affected 82.4% (14/17) of those with MICs of 1 g/ml and 97.4% (69/71) and 100% (6/6) of the strains with GSK1322322 MICs of 2 and 4 g/ml, respectively. Therefore, although additional studies with larger numbers of strains at the extreme ends of the MIC distribution would be revealing, it seems that GSK1322322 has a stronger sub-MIC effect on strains with higher MICs. This observation could explain the results obtained in the efficacy studies with GSK466222, as the initial in vitro growth of the two S. aureus strains with higher MICs, PK2 and X32601, was inhibited at concentrations 1/16ϫ and 1/8ϫ MIC, respectively, whereas concentrations of 1/2ϫ MIC were necessary to inhibit growth of S. aureus 218845 (data not shown). Therefore, the amount of GSK466222 necessary to inhibit the first 6 h of growth of all three strains would be very similar and, as the compound is dosed twice a day for 4 days, this effect would be exerted at regular intervals. In addition, recent pharmacokinetic/pharmacodynamic (PK/PD) analyses of GSK1322322 in eight S. aureus strains with MICs ranging from 0.5 to 4 g/ml demonstrated a lack of correlation between the MIC and the free area under the concentration-time curve (AUC) necessary for efficacy. Instead, efficacious AUCs were similar against all strains, independent of their MIC (T. Lewandowski, J. L. Hoover, and S. Rittenhouse, presentation at the 23rd European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 27 to 30 April 2013).
Although an extensive bioinformatic analysis comparing the genomes of strains inhibited and not inhibited by sub-MICs of PDF inhibitors was conducted, no differences were identified that could explain this phenomenon. While no changes were observed between the promoter/coding regions of the pdf genes from strains showing a potent sub-MIC effect and those that did not, a thorough transcription analysis of this gene might provide some insight into the possible induction of PDF expression by PDF inhibitors in some S. aureus strains.
Whereas the in vitro activity of an antibiotic can be readily determined by simple methodologies, its efficacy in vivo is the result of the complex interrelation of a number of parameters that can be, at best, measured only individually. Consequently, PK/PD studies are a critical step in the process of predicting the antibiotic doses necessary for clinical efficacy. Although PK/PD parameters have been shown to be good predictors of efficacy, they are always reported in relation to the in vitro MIC. Not taken into account is any effect that the antibiotic may have at subinhibitory concentrations, a situation frequently encountered during the normal course of antibiotic therapy. Specifically in S. aureus, it has already been reported that subinhibitory concentrations of certain antibiotics can inhibit exoprotein production (28), including critical virulence factors, such as alpha-toxin (29, 30) , increase susceptibility to phagocytosis (29) , and modulate adherence to fibronectin (31, 32) and can even inhibit biofilm formation (33, 34) . These effects may be important in the successful treatment of S. aureus infections and should perhaps be taken into consideration in the selection of therapy (30) .
In conclusion, we report that sub-MICs of PDF inhibitors prevent the first 6 h of S. aureus in vitro growth. In addition, our results indicate that this growth inhibition is more pronounced for strains at the higher end of the MIC distribution and, consequently, there may not be a linear relationship, within the wildtype frequency distribution, between the concentration of compound necessary for efficacy and the MIC of the strain causing the infection. Additional studies will be necessary to elucidate the mechanism behind this unusual observation and to understand any potential implications for the clinical efficacy of GSK1322322 and other PDF inhibitors against S. aureus infections.
